To date, there are few clinical trials with highly variable results regarding the pro-cognitive effect of IL-6 modulators; most of these studies have been conducted in samples of patients with Alzheimer’s disease [64], making direct extrapolation to our population of interest difficult. The gene discussed is IL6; the disease is early-onset autosomal dominant Alzheimer disease.